Upfront Lenalidomide in Follicular Lymphoma: Time has Come or Not?

  • Vikas Garg
  • Ajay GogiaEmail author
  • Gopila Gupta


  1. 1.
    Morschhauser F, Fowler NH, Feugier P et al (2018) Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med 379:934–947CrossRefGoogle Scholar
  2. 2.
    Fowler NH, Davis RE, Rawal S et al (2014) Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol 15:1311–1318CrossRefGoogle Scholar
  3. 3.
    Flinn IW, van der Jagt R, Kahl BS et al (2014) Randomized trial of bendamustine rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study. Blood 123:2944–2952CrossRefGoogle Scholar
  4. 4.
    Rummel MJ, Niederle N, Maschmeyer G et al (2013) Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label multicentre, randomised, phase 3 noninferiority trial. Lancet 381:1203–1210CrossRefGoogle Scholar
  5. 5.
    Paikaray SK, Gogia A, Kumar A et al (2018) A phase III open label randomized study to compare the efficacy of lenalidomide-rituximab vs bendamustine-rituximab in treatment naive follicular lymphoma [Abstract]. J Clin Oncol 36(Suppl 15):e19552CrossRefGoogle Scholar

Copyright information

© Indian Society of Hematology and Blood Transfusion 2018

Authors and Affiliations

  1. 1.Department of Medical OncologyDr. B.R.A. IRCH All India Institute of Medical Sciences, DelhiNew DelhiIndia
  2. 2.Department of HematologyAll India Institute of Medical Sciences, DelhiNew DelhiIndia

Personalised recommendations